FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W177904137> ?p ?o ?g. }

• W177904137 endingPage "392" @default.
• W177904137 startingPage "389" @default.
• W177904137 abstract "Non-inferiority studies are appearing in medical journals with increasing frequency. At first glance, one might think the intent of such a study is to publish negative results or, in the worst case scenario, to create a marketing ploy that would have us consider replacing a tried-and-true treatment with a new one. Nevertheless, these trials can bring value by introducing new treatments that may be therapeutically similar to the standard treatment but with certain advantages. In this issue of the Journal, Merry et al. show that clevidipine, a short-acting dihydropyridine calcium channel antagonist, is non-inferior to nitroglycerin (NTG) in the pre-bypass period of patients undergoing cardiac surgery. The information needed for a clinician to assess a non-inferiority trial is highlighted in the context of this study. The non-inferiority trial attempts to show that the new treatment is not an unacceptably worse alternative to the standard. This is done by stating a margin of noninferiority for the effect of the treatment. The noninferiority margin describes the amount of reduction in efficacy that will be tolerated. As long as the new treatment is not worse than the standard treatment by this margin, the new treatment would be considered non-inferior. What is the rationale for performing a non-inferiority trial? In the regulatory setting, the efficacy of a new treatment is usually shown in a placebo-controlled trial. In some situations, however, it would be unethical to withhold treatment; hence, a non-inferiority trial is used to indirectly show the efficacy of the new treatment. Alternatively, a trial sponsor may have a new treatment that provides only a small advantage over the standard. Showing this superiority would require a very large study, while noninferiority could be shown with a much smaller sample. In the non-regulatory setting, non-inferiority trials are most often used to show that an alternative treatment with advantages regarding safety, convenience, or cost has an efficacy similar to, or at least not much worse than, the standard treatment. The first order of business is to decide if a noninferiority design is reasonable. The reader must question whether the purported advantages of the new treatment over the standard would justify adopting the new treatment should non-inferiority be shown. Typical advantages are price, ease of use, or a reduced number of side effects. If the answer is ‘‘no’’, then the non-inferiority design should be abandoned. If the answer is ‘‘yes’’, then the reader will need to consider the next issue, i.e., the assay sensitivity and the consistency of the control treatment. In a noninferiority trial, two comparisons are made: the explicit comparison of the new treatment with an active control treatment and the implicit comparison of the active control treatment with placebo. Generally, there is no placebo control in these studies so the reader must be convinced that the treatment (active control) against which the new treatment is being compared would provide effective management (i.e., be superior to a placebo) in the context in which it is being used. This is referred to as the assay sensitivity. If the efficacy of the standard is border-line, then showing that the new treatment is non-inferior is of little value as it may in fact be no different from a placebo. It is also important that previous trials using the standard P. M. A. Brasher, PhD Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada" @default.
• W177904137 created "2016-06-24" @default.
• W177904137 creator A5060734842 @default.
• W177904137 creator A5090706383 @default.
• W177904137 date "2014-03-08" @default.
• W177904137 modified "2023-10-16" @default.
• W177904137 title "Understanding non-inferiority trials: an introduction" @default.
• W177904137 cites W157051678 @default.
• W177904137 cites W1977954727 @default.
• W177904137 cites W1987467897 @default.
• W177904137 cites W2104524275 @default.
• W177904137 cites W2128842690 @default.
• W177904137 cites W2171466180 @default.
• W177904137 doi "https://doi.org/10.1007/s12630-014-0132-y" @default.
• W177904137 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24610516" @default.
• W177904137 hasPublicationYear "2014" @default.
• W177904137 type Work @default.
• W177904137 sameAs 177904137 @default.
• W177904137 citedByCount "5" @default.
• W177904137 countsByYear W1779041372018 @default.
• W177904137 countsByYear W1779041372019 @default.
• W177904137 countsByYear W1779041372020 @default.
• W177904137 countsByYear W1779041372022 @default.
• W177904137 countsByYear W1779041372023 @default.
• W177904137 crossrefType "journal-article" @default.
• W177904137 hasAuthorship W177904137A5060734842 @default.
• W177904137 hasAuthorship W177904137A5090706383 @default.
• W177904137 hasBestOaLocation W1779041371 @default.
• W177904137 hasConcept C15744967 @default.
• W177904137 hasConceptScore W177904137C15744967 @default.
• W177904137 hasIssue "5" @default.
• W177904137 hasLocation W1779041371 @default.
• W177904137 hasLocation W1779041372 @default.
• W177904137 hasOpenAccess W177904137 @default.
• W177904137 hasPrimaryLocation W1779041371 @default.
• W177904137 hasRelatedWork W2053487507 @default.
• W177904137 hasRelatedWork W2067108088 @default.
• W177904137 hasRelatedWork W2077865380 @default.
• W177904137 hasRelatedWork W2083375246 @default.
• W177904137 hasRelatedWork W2085372204 @default.
• W177904137 hasRelatedWork W2134894512 @default.
• W177904137 hasRelatedWork W2748952813 @default.
• W177904137 hasRelatedWork W2765597752 @default.
• W177904137 hasRelatedWork W2899084033 @default.
• W177904137 hasRelatedWork W2931662336 @default.
• W177904137 hasVolume "61" @default.
• W177904137 isParatext "false" @default.
• W177904137 isRetracted "false" @default.
• W177904137 magId "177904137" @default.
• W177904137 workType "article" @default.